While passive targeting uses the above inherent physical properties, active nanocarriers further improve tumour-lineage specific targeting by using NPs with antibodies or ligands directed towards specific tumour antigens, e.g., anti-HER2 antibody-PEG liposomes targeting HER+ BC [91]. The gene discussed is ERBB2; the disease is breast cancer.